Matt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 13,235 shares of the business's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $24,352.40. Following the transaction, the chief financial officer now owns 198,210 shares in the company, valued at $364,706.40. This trade represents a 6.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Acumen Pharmaceuticals Trading Down 1.1 %

Shares of Acumen Pharmaceuticals stock traded down $0.02 on Tuesday, hitting $1.83. 184,478 shares of the company traded hands, compared to its average volume of 247,994. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $109.95 million, a PE ratio of -1.33 and a beta of 0.02. The stock's 50 day moving average price is $2.27 and its 200-day moving average price is $2.52. Acumen Pharmaceuticals, Inc. has a 52 week low of $1.69 and a 52 week high of $5.09.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.14). During the same quarter in the previous year, the company posted ($0.24) EPS. Equities research analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several institutional investors have recently bought and sold shares of ABOS. Renaissance Technologies LLC acquired a new stake in shares of Acumen Pharmaceuticals in the 2nd quarter worth $818,000. Franklin Resources Inc. grew its holdings in shares of Acumen Pharmaceuticals by 5.4% during the third quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company's stock valued at $8,340,000 after buying an additional 181,451 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Acumen Pharmaceuticals in the 2nd quarter valued at $306,000. State Street Corp lifted its position in Acumen Pharmaceuticals by 18.3% during the 3rd quarter. State Street Corp now owns 516,406 shares of the company's stock worth $1,281,000 after acquiring an additional 79,841 shares during the period. Finally, Murchinson Ltd. acquired a new position in shares of Acumen Pharmaceuticals in the second quarter valued at about $136,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.